Внесок користувача
- 10:25, 28 червня 2017 (різн. • історія) . . (+3665) . . Н Although, we attempted to account for variations inside the menstrual cycle, the majority of the samples incorporated in our evaluation have been obtained throughout the proliferative phase (Створена сторінка: anced preclinical improvement as anticancer and antiangiogenic agents. The mechanism of action of this extremely potent compound class entails the depolymerizat...) (поточна)
- 21:22, 26 квітня 2017 (різн. • історія) . . (+3637) . . Н To confirm the dissociation from the complex, mTOR was immunoprecipitated from manage and PEITC treated cells and immunoblotted for Rictor and Raptor (Створена сторінка: Therefore, we investigated whether mixture of Nutlin-3a and TNF-a in sarcoma cells interferes with the NF-kB-activity, which could clarify the observed potentia...) (поточна)
- 20:19, 26 квітня 2017 (різн. • історія) . . (+3806) . . Н To confirm the dissociation from the complex, mTOR was immunoprecipitated from handle and PEITC treated cells and immunoblotted for Rictor and Raptor (Створена сторінка: , treatment of addition of cultured primary uterine leiomyoma smooth muscle cells using a DNMT inhibitor restored DLEC1 expression. The DLEC1 gene encodes a 166...) (поточна)